Redhill Biopharma Ltd.

Good day and welcome to the Redhill Biopharmers 4th Quarter and 4th Year 2021 Financial Results Conference Call. All participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. At this time, I would like to introduce the conference call, Redhill's CEO, Gerard Ben Asher, Guy Goldberg, Chief Business Officer, Gilad Rade, Chief Operating Officer, Rob Jackson, Senior VP Sales and Marketing, Rick Scruggs, Chief Commercial Officer, and Mika Ben-Torin, Chief Financial Officer. We have additional senior management team members available to answer questions during the Q&A session, including Dr. June Alamanov, Chief Medical Officer, and Dr. Mark Levitt, Chief Scientific Officer. Before we begin, we will read from Redhill's safe harbor statement. Please go ahead.

Thank you, Sharon. This conference call may contain projections or other forward-looking statements regarding future events or the future performance of Redhill, including statements with respect to the business financial results, promotion and other efforts related to Redhill's commercialization activities and the initiation, timing, progress and results of Redhill's research, manufacturing, preclinical studies, clinical trials, marketing applications and approvals, if any, including the clinical trials of Opagonib and RHP107 for the treatment of COVID-19 and RHP204 for NPM disease. These statements are only predictions and RADL cannot guarantee that they will in fact occur. RADL does not assume any obligation to update that information. Actual events, performance, timing, results, or commercialization activities may differ materially from what Redhill projects today. Additional information concerning factors that could cause actual events, performance, timing, results, or commercialization activities to materially differ from those contained in the forward-looking statements can be found in the company's annual report on Form 20-F filed with the SEC on March 17, 2022, and in its other findings with the Securities and Exchange Commission. I will now turn the call to Torben Escher, Red Hill Shield.

Thank you, Alexandra. Good day, everyone, and thank you for joining our fourth quarter and full year 2021 earnings call, during which we'll be presenting R&D, commercial, and financial highlights. First and foremost, I would like to thank the entire Red Hill team for their remarkable achievements in the last year. Against the pandemic backdrop, the Red Hill team delivered record revenues and first positive commercial operations contribution in the fourth quarter of 2021. A strong fourth quarter for both Talisia and Movantix, coupled with disciplined cost efficiency measures and intensive out-licensing and in-licensing activities, set us up for rapid organic and non-organic growth in 2022 and beyond. Rob Jackson, who is heading our marketing and sales, will further elaborate shortly. Turning to R&D, Red Hill remains at the forefront of the global search for much-needed novel oral COVID-19 therapies, particularly so given the frequent emergence of new variants such as Omicron and most recently, BA.2. Our highly capable R&D team has delivered exciting efficacy data with both of Pagani and RHB107, our variant-agnostic investigational oral novel oral candidates for the treatment of hospitalized and non-hospitalized COVID-19 patients. At the same time, our ongoing phase three study with RHB204 as the most advanced first-line standalone potential treatment for NTM infection is being accelerated. Gilad Raday, our Chief Operating Officer, will elaborate about our R&D program shortly. I will now be turning to our Chief Business Officer, Guy Goldsberg, and the team for our presentation to be followed by Q&A session. Thank you, Dror.